Stock Track | Eli Lilly Plummets 5.90% in Pre-market Amid Competitive Pressure from Hims & Hers and Novo Nordisk Guidance Disappointment

Stock Track

Feb 05

Eli Lilly's stock experienced a significant pre-market plummet of 5.90% on Thursday, as negative sentiment swept through the pharmaceutical sector.

The sharp decline came despite multiple analyst upgrades for Eli Lilly, with the downward pressure primarily attributed to two key factors. First, a Reuters report indicated that Hims & Hers Health is launching a copy of Novo Nordisk's Wegovy weight-loss pill at a price of $49, introducing new competitive pressure in the lucrative GLP-1 drug market. Second, sector-wide concerns emerged following disappointing guidance from Novo Nordisk, a major competitor in the weight-loss drug space, whose shares tumbled 19% in Copenhagen trading.

These developments overshadowed Eli Lilly's own strong fourth-quarter earnings report, which showed rising profits amid surging demand for its weight-loss drugs, and numerous analyst price target increases from firms including Goldman Sachs, JP Morgan, Morgan Stanley, and Wells Fargo.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1177582701"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177582701\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1177582701?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 23:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177582701","market":"nz","top_or_hot":-1,"title":"Stock Track | Eli Lilly Plummets 5.90% in Pre-market Amid Competitive Pressure from Hims & Hers and Novo Nordisk Guidance Disappointment","media":"Stock Track","content":"<p>Eli Lilly's stock experienced a significant pre-market plummet of 5.90% on Thursday, as negative sentiment swept through the pharmaceutical sector.</p><p>The sharp decline came despite multiple analyst upgrades for Eli Lilly, with the downward pressure primarily attributed to two key factors. First, a Reuters report indicated that Hims & Hers Health is launching a copy of Novo Nordisk's Wegovy weight-loss pill at a price of $49, introducing new competitive pressure in the lucrative GLP-1 drug market. Second, sector-wide concerns emerged following disappointing guidance from Novo Nordisk, a major competitor in the weight-loss drug space, whose shares tumbled 19% in Copenhagen trading.</p><p>These developments overshadowed Eli Lilly's own strong fourth-quarter earnings report, which showed rising profits amid surging demand for its weight-loss drugs, and numerous analyst price target increases from firms including Goldman Sachs, JP Morgan, Morgan Stanley, and Wells Fargo.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Eli Lilly Plummets 5.90% in Pre-market Amid Competitive Pressure from Hims & Hers and Novo Nordisk Guidance Disappointment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Eli Lilly Plummets 5.90% in Pre-market Amid Competitive Pressure from Hims & Hers and Novo Nordisk Guidance Disappointment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-05 23:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Eli Lilly's stock experienced a significant pre-market plummet of 5.90% on Thursday, as negative sentiment swept through the pharmaceutical sector.</p><p>The sharp decline came despite multiple analyst upgrades for Eli Lilly, with the downward pressure primarily attributed to two key factors. First, a Reuters report indicated that Hims & Hers Health is launching a copy of Novo Nordisk's Wegovy weight-loss pill at a price of $49, introducing new competitive pressure in the lucrative GLP-1 drug market. Second, sector-wide concerns emerged following disappointing guidance from Novo Nordisk, a major competitor in the weight-loss drug space, whose shares tumbled 19% in Copenhagen trading.</p><p>These developments overshadowed Eli Lilly's own strong fourth-quarter earnings report, which showed rising profits amid surging demand for its weight-loss drugs, and numerous analyst price target increases from firms including Goldman Sachs, JP Morgan, Morgan Stanley, and Wells Fargo.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"","article_id":"1177582701","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177582701","pubTimestamp":1770305863,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Eli Lilly's stock experienced a significant pre-market plummet of 5.90% on Thursday, as negative sentiment swept through the pharmaceutical sector.The sharp decline came despite multiple analyst...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来"},"translate_title":"个股追踪|Hims&Hers竞争压力和诺和诺德指引令人失望礼来盘前暴跌5.90%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"Eli Lilly's stock experienced a significant pre-market plummet of 5.90% on Thursday, as negative sentiment swept through the pharmaceutical sector.The sharp decline came despite multiple analyst upgrades for Eli Lilly, with the downward pressure primarily attributed to two key factors. First, a Reuters report indicated that Hims & Hers Health is launching a copy of Novo Nordisk's Wegovy weight-loss pill at a price of $49, introducing new competitive pressure in the lucrative GLP-1 drug market. Second, sector-wide concerns emerged following disappointing guidance from Novo Nordisk, a major competitor in the weight-loss drug space, whose shares tumbled 19% in Copenhagen trading.These developments overshadowed Eli Lilly's own strong fourth-quarter earnings report, which showed rising profits amid surging demand for its weight-loss drugs, and numerous analyst price target increases from firms including Goldman Sachs, JP Morgan, Morgan Stanley, and Wells Fargo.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}